[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617168":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":75,"collaborators":21,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":21,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":21,"enrollmentInfo":86,"targetDuration":21,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":56,"whyStopped":21,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Nuvectis Pharma, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Exploration (Part 1)","EXPERIMENTAL","Escalating doses of NXP900 given with osimertinib",[13,14],"Drug: NXP900","Drug: Osimertinib",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","NXP900","NXP900 is an orally administered inhibitor of SRC family kinases (SFK)",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Osimertinib","Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor",[9],[27],{"name":28,"affiliation":29,"role":30},"Zofia Piotrowska, MD, MHS","Massachusetts General Hospital","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Erin Belshaw","CONTACT","12016278129","ebelshaw@nuvectis.com",{"name":38,"role":34,"phone":21,"phoneExt":21,"email":39},"Shay Shemesh","sshemesh@nuvectis.com",[41,54,65],{"facility":29,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":21},"NOT_YET_RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-71.05977,42.35843,{"lat":52,"lon":51},{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":46,"countryCode":47,"cosmosGeoPoint":60,"geoPoint":64,"contacts":21},"NEXT Houston","RECRUITING","Houston","Texas","77054",{"type":49,"coordinates":61},[62,63],-95.36327,29.76328,{"lat":63,"lon":62},{"facility":66,"status":56,"city":67,"state":68,"zip":69,"country":46,"countryCode":47,"cosmosGeoPoint":70,"geoPoint":74,"contacts":21},"NEXT Virginia","Fairfax","Virginia","22031",{"type":49,"coordinates":71},[72,73],-77.30637,38.84622,{"lat":73,"lon":72},{"type":76,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100617168","phase-1-study-of-nxp900-with-osimertinib-in-subjects-with-advanced-egfr-mutated-non-small-cell-lung-cancer-100617168",false,"NCT07315113","Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. 18 years old or older.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.\n5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.\n\nExclusion Criteria:\n\n1. Subject's cancer has a known oncogenic driver alteration other than EGFR.\n2. Known EGFR mutations that cause resistance to osimertinib\n3. Known human epidermal growth factor receptor 2 (HER2) overexpression\n4. Any contraindications to treatment with osimertinib","ALL","18 Years",{"count":87,"type":88},18,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)",[94,95],"EGFR Mutation Positive Non-small Cell Lung Cancer","EGFR Mutated Non-small Cell Lung Cancer Patients",[97,98,99,100,101,102,18,103],"EGFR","Epidermal growth factor receptor","NSCLC","non-small cell lung cancer","lung cancer","osimertinib","EGFR mutation","2025-12-18",{"date":106,"type":107},"2026-01-02","ACTUAL",{"date":104,"type":107},{"date":110,"type":88},"2027-06",{"name":5,"class":6},3]